Clinically Relevant Reagents

Made Better, Work Better, At a Lower Cost

SBT introduces a next generation anti CD45 reagent product line.

Platform production of clinically relevant reagents such as monoclonal antibodies (Mab’s) and antibody-like proteins such as single-chain antibody fragments (scFv’s) can require years of intensive laboratory and investment resources!

StableBody Technologies, LLC (SBT) has developed the BioDesign System (BDS™), a unique, state-of-the-art bioinformatic process for accelerating and achieving superior performance composition in antibody engineering.